Tag: Cancer Care

  • Older Iranian adults with colorectal cancer reported layered existential distress

    What the study found

    The study found that older Iranian adults with colorectal cancer experienced layered existential distress. This distress was described through reduced self-worth, fear and uncertainty about death, and strained or disrupted relationships.

    Why the authors say this matters

    The authors conclude that the findings can guide supportive cancer care that addresses existential and spiritual needs alongside physical care. They say the results highlight psychosocial dimensions that should be considered in culturally informed interventions.

    What the researchers tested

    The researchers used a qualitative descriptive phenomenological design, which explores lived experience. They interviewed 17 adults age 65 or older with confirmed colorectal cancer at a cancer center in northern Iran and analyzed the interviews using Colaizzi’s seven-step method.

    What worked and what didn't

    Three themes emerged: inadequate self-realization, confronting uncertainty and death, and disruption of meaningful relationships. Participants described diminished inner value and guilt about burdening family, feeling lost and fearful of the unknown, and stigma, humiliation, and self-imposed isolation.

    What to keep in mind

    The findings come from 17 older adults at one cancer center in northern Iran, so the scope is limited to this group and setting. The abstract does not describe additional limitations.

    • Seventeen adults age 65 or older with confirmed colorectal cancer were interviewed.
    • Three themes described the experience of existential distress.
    • Participants reported diminished self-worth and guilt about being a family burden.
    • Uncertainty, fear of the unknown, and death were central concerns.
    • Stigma and social humiliation were linked to isolation and disrupted relationships.
  • Denosumab plus hip-sparing surgery showed good outcomes

    What the study found

    The study found that preoperative denosumab, a drug used to treat certain bone tumors, combined with curettage after surgical dislocation of the hip was associated with good clinical and functional outcomes in patients with giant cell tumor of bone in the femoral head and neck. All patients kept their native hip joints, and no local recurrence or metastasis was seen at final follow-up.

    Why the authors say this matters

    The authors conclude that this approach may offer a way to treat this difficult tumor location while preserving the native hip joint. The study suggests the treatment had a favorable safety profile, with no drug-related complications observed.

    What the researchers tested

    This was a single-center retrospective study of 14 eligible patients treated between 2016 and 2023. Each patient received three cycles of preoperative denosumab, then underwent surgical dislocation of the hip with curettage of the lesion, and was followed for 24 to 50 months.

    What worked and what didn't

    All 14 patients completed denosumab treatment and successful surgery. Imaging showed shrinkage of residual cavities, blurred boundaries, progressive bone sclerosis, and trabecular bone regeneration at the surgical site, and functional scores improved significantly at 1 year and were excellent in all patients. According to RECIST 1.1, 11 patients had partial remission and 3 had stable disease; no postoperative complications, local recurrence, or metastatic progression were reported.

    What to keep in mind

    The report includes only 14 patients from one center, so the findings are limited to this small group. The abstract does not describe a comparison group, and broader limitations are not detailed in the available summary.

    • Fourteen patients with giant cell tumor of bone in the femoral head and neck were included.
    • All patients received three preoperative cycles of denosumab before surgery.
    • All patients underwent surgical dislocation of the hip with curettage and kept their native hip joints.
    • Functional scores improved significantly after treatment, and all patients reached excellent function.
    • No postoperative complications, local recurrence, or metastatic progression were reported during follow-up.
  • Three biomarkers were linked to chondrosarcoma angiogenesis and stress response

    What the study found

    The study identified three potential biomarkers for chondrosarcoma: HSPA8, LMNA, and SERPINH1. Their higher expression was confirmed in chondrosarcoma patients, and the authors link them to angiogenesis and the integrated stress response, a cellular stress pathway.

    Why the authors say this matters

    The authors conclude that these biomarkers may offer novel insights for developing targeted therapies for chondrosarcoma associated with angiogenesis and the integrated stress response. The study suggests they could help clarify molecular mechanisms in the disease.

    What the researchers tested

    The researchers analyzed chondrosarcoma data from the Gene Expression Omnibus, a public repository of gene-expression datasets. They used differential expression analysis, weighted gene co-expression network analysis, enrichment analysis, molecular network analyses, compound prediction, molecular docking, single-cell RNA sequencing from GSE184118, pseudo-time analysis, cell communication analysis, and RT-qPCR confirmation.

    What worked and what didn't

    Three biomarkers, HSPA8, LMNA, and SERPINH1, were identified and their expression trends were consistent across the GSE30835 and GSE22855 datasets. The biomarkers were reported to be enriched in pathways related to protein degradation, had predicted regulatory relationships with transcription factors, microRNAs, and long non-coding RNAs, and showed stable binding affinity with adenosine diphosphate and lonafarnib. Pseudo-time and cell communication analyses linked their expression to differentiation status in stromal cells and interactions between stromal cells and chondroid cluster 1, and RT-qPCR confirmed higher expression in patients.

    What to keep in mind

    The abstract does not describe detailed study limitations. The findings are based on public datasets and validation in the reported samples, so the summary here is limited to the evidence described in the abstract.

    • HSPA8, LMNA, and SERPINH1 were identified as potential chondrosarcoma biomarkers.
    • Their expression was consistent across the GSE30835 and GSE22855 datasets.
    • RT-qPCR confirmed higher expression of all three biomarkers in chondrosarcoma patients.
    • Single-cell RNA sequencing analysis linked biomarker expression to stromal cell differentiation status.
    • Cell communication analysis found strong interactions between stromal cells and chondroid cluster 1.